Mechanistic role of miR-375 in regulating PDPK1 to promote progression of small bowel neuroendocrine tumors: a silico analysis
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.This study identified five microRNAs (miRNAs) as potential diagnostic markers for small bowel neuroendocrine tumors (SBNETs). MiR-375 regulating PDPK1 shows promise as a therapeutic target for SBNETs.
Area Of Science
- Oncology
- Molecular Biology
- Genomics
Background
- Small bowel neuroendocrine tumors (SBNETs) incidence is rising, necessitating novel therapeutic strategies to improve patient survival.
- Current treatment options for SBNETs are limited, highlighting the urgent need for new diagnostic and therapeutic approaches.
Purpose Of The Study
- To identify potential diagnostic and therapeutic candidate markers for small bowel neuroendocrine tumors (SBNETs).
- To explore the role of microRNAs (miRNAs) and messenger RNAs (mRNAs) in SBNET development and progression.
Main Methods
- Analysis of miRNA and mRNA expression profiles from public datasets (GSE70534, GSE103317, GSE65286) comparing SBNETs with control samples.
- Identification of differentially expressed miRNAs (DEmiRs) and mRNAs (DEmRs), followed by enrichment and coexpression analyses.
- Application of the XGBoost algorithm to identify feature miRNAs and construction of a regulatory network, including drug targeting and immune microenvironment evaluation.
Main Results
- Fifty-seven common DEmiRs were identified, with five feature miRNAs (hsa-miR-375, hsa-miR-107, hsa-miR-1180, hsa-miR-330-3p, hsa-miR-328) highlighted.
- PDPK1 was identified as a key target gene, showing the strongest correlation with the therapeutic agent 177Lu-DOTATATE, regulated by miR-375.
- PDPK1 expression correlated with immune cell populations (eosinophils, cytotoxic cells) and immune checkpoints within the SBNET microenvironment.
Conclusions
- Five identified feature miRNAs demonstrate potential as diagnostic markers for SBNETs.
- The miR-375/PDPK1 axis presents a promising therapeutic candidate marker for SBNET treatment.
- Further investigation into these markers could lead to improved diagnostic accuracy and targeted therapies for SBNET patients.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...